Thank you for your message about Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). You must verify your email address to receive further communication about this trial. Please check your email for a verification message.
We're sorry, your verification code has expired. Please submit another form using the button below to receive communications about your preferred clinical trial study.
Clinical Trial Study Email Verified Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)